Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 9;15:3. doi: 10.1186/s13045-021-01219-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 3 — Post-vaccine neutralisation of live Wuhan virus and Delta variant. A (i) Maximum neutralisation of live virus using post-vaccine sera from healthy donors (HD; n = 94) and patients with CLL (n = 94) (p < 0.0001 Kruskal–Wallis). (ii) Maximum neutralisation in 53 CLL patients with a positive spike-specific antibody response following second vaccine (p < 0.0001). (iii) Maximum neutralisation using post-vaccine sera in HD and patients with serological evidence of previous natural infection with SARS-CoV-2. B Correlation between ND50 value against Wuhan virus or delta variant and spike-specific antibody titre in HD (Wuhan r = 0.80 and Delta r = 0.77; p < 0.0001) and CLL patients with a positive antibody response (Wuhan r = 0.60 and for Delta r = 0.61; p = < 0.0001)